JP2018526407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526407A5 JP2018526407A5 JP2018512564A JP2018512564A JP2018526407A5 JP 2018526407 A5 JP2018526407 A5 JP 2018526407A5 JP 2018512564 A JP2018512564 A JP 2018512564A JP 2018512564 A JP2018512564 A JP 2018512564A JP 2018526407 A5 JP2018526407 A5 JP 2018526407A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- use according
- pharmaceutical composition
- valyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- 230000006996 mental state Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 229940100691 oral capsule Drugs 0.000 claims description 3
- 229940096978 oral tablet Drugs 0.000 claims description 3
- 239000007935 oral tablet Substances 0.000 claims description 3
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 229960003570 tramiprosate Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216404P | 2015-09-10 | 2015-09-10 | |
| US62/216,404 | 2015-09-10 | ||
| US201662290287P | 2016-02-02 | 2016-02-02 | |
| US62/290,287 | 2016-02-02 | ||
| US201662302027P | 2016-03-01 | 2016-03-01 | |
| US62/302,027 | 2016-03-01 | ||
| US201662365809P | 2016-07-22 | 2016-07-22 | |
| US62/365,809 | 2016-07-22 | ||
| PCT/US2016/051091 WO2017044840A1 (en) | 2015-09-10 | 2016-09-09 | Methods of treating neurodegenerative disorders in a particular patient population |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020161995A Division JP7128536B2 (ja) | 2015-09-10 | 2020-09-28 | 特定の患者集団において神経変性障害を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526407A JP2018526407A (ja) | 2018-09-13 |
| JP2018526407A5 true JP2018526407A5 (enExample) | 2019-10-24 |
| JP6789579B2 JP6789579B2 (ja) | 2020-11-25 |
Family
ID=58240195
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512564A Active JP6789579B2 (ja) | 2015-09-10 | 2016-09-09 | 特定の患者集団において神経変性障害を処置する方法 |
| JP2020161995A Active JP7128536B2 (ja) | 2015-09-10 | 2020-09-28 | 特定の患者集団において神経変性障害を処置する方法 |
| JP2022128786A Pending JP2022145949A (ja) | 2015-09-10 | 2022-08-12 | 特定の患者集団において神経変性障害を処置する方法 |
| JP2025023627A Pending JP2025065545A (ja) | 2015-09-10 | 2025-02-17 | 特定の患者集団において神経変性障害を処置する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020161995A Active JP7128536B2 (ja) | 2015-09-10 | 2020-09-28 | 特定の患者集団において神経変性障害を処置する方法 |
| JP2022128786A Pending JP2022145949A (ja) | 2015-09-10 | 2022-08-12 | 特定の患者集団において神経変性障害を処置する方法 |
| JP2025023627A Pending JP2025065545A (ja) | 2015-09-10 | 2025-02-17 | 特定の患者集団において神経変性障害を処置する方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11191742B2 (enExample) |
| EP (2) | EP3347002B1 (enExample) |
| JP (4) | JP6789579B2 (enExample) |
| KR (2) | KR102412997B1 (enExample) |
| CN (3) | CN116712423A (enExample) |
| AU (1) | AU2016319107B2 (enExample) |
| CA (1) | CA2997376C (enExample) |
| DK (1) | DK3347002T3 (enExample) |
| ES (1) | ES2952727T3 (enExample) |
| FI (1) | FI3347002T3 (enExample) |
| HR (1) | HRP20230809T1 (enExample) |
| HU (1) | HUE062511T2 (enExample) |
| LT (1) | LT3347002T (enExample) |
| MD (1) | MD3347002T2 (enExample) |
| MX (2) | MX392677B (enExample) |
| PL (1) | PL3347002T3 (enExample) |
| PT (1) | PT3347002T (enExample) |
| RS (2) | RS68293B1 (enExample) |
| SI (1) | SI3347002T1 (enExample) |
| SM (2) | SMT202300250T1 (enExample) |
| WO (1) | WO2017044840A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2960625T3 (es) | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| CN114805211B (zh) | 2017-03-21 | 2024-08-23 | 润佳（苏州）医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| MX2021001287A (es) * | 2018-08-01 | 2021-07-15 | Alzheon Inc | Métodos para tratar trastornos neurodegenerativos. |
| SI4296670T1 (sl) * | 2018-08-01 | 2026-04-30 | Alzheon, Inc. | Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| PH12021553196A1 (en) * | 2019-06-17 | 2022-11-07 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| AU2022405026A1 (en) * | 2021-12-09 | 2024-06-20 | Alzheon, Inc. | Alz-801 for use in treating alzheimer's disease |
| WO2023150381A1 (en) * | 2022-02-07 | 2023-08-10 | Alzheon, Inc. | Alz-801 for use in treating a covid-19 associated neurological symptom |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| CA2142300C (en) | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| EP1664601B1 (en) | 2003-08-11 | 2016-10-12 | California Institute Of Technology | Microfluidic large scale integration |
| US20060251714A1 (en) * | 2005-04-12 | 2006-11-09 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| SI2089417T1 (sl) | 2006-10-12 | 2015-04-30 | Bhi Limited Partnership | Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline |
| SG173409A1 (en) | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US20120009125A1 (en) | 2010-07-06 | 2012-01-12 | Lombard Jay L | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| MX353096B (es) | 2010-08-19 | 2017-12-19 | Buck Institute For Age Res Star | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
| US20150118231A1 (en) * | 2012-05-08 | 2015-04-30 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| HUE044737T2 (hu) * | 2013-05-06 | 2019-11-28 | Baxalta Inc | Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel |
| NZ723884A (en) | 2014-02-08 | 2023-02-24 | Genentech Inc | Methods of treating alzheimer’s disease |
| ES2960625T3 (es) * | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
-
2016
- 2016-09-09 EP EP16845181.3A patent/EP3347002B1/en active Active
- 2016-09-09 PL PL16845181.3T patent/PL3347002T3/pl unknown
- 2016-09-09 SM SM20230250T patent/SMT202300250T1/it unknown
- 2016-09-09 ES ES16845181T patent/ES2952727T3/es active Active
- 2016-09-09 RS RS20260811A patent/RS68293B1/en unknown
- 2016-09-09 MD MDE20180700T patent/MD3347002T2/ro unknown
- 2016-09-09 WO PCT/US2016/051091 patent/WO2017044840A1/en not_active Ceased
- 2016-09-09 DK DK16845181.3T patent/DK3347002T3/da active
- 2016-09-09 SI SI201631729T patent/SI3347002T1/sl unknown
- 2016-09-09 KR KR1020187009381A patent/KR102412997B1/ko active Active
- 2016-09-09 US US15/758,405 patent/US11191742B2/en active Active
- 2016-09-09 JP JP2018512564A patent/JP6789579B2/ja active Active
- 2016-09-09 HU HUE16845181A patent/HUE062511T2/hu unknown
- 2016-09-09 LT LTEPPCT/US2016/051091T patent/LT3347002T/lt unknown
- 2016-09-09 AU AU2016319107A patent/AU2016319107B2/en active Active
- 2016-09-09 CN CN202310582394.5A patent/CN116712423A/zh active Pending
- 2016-09-09 HR HRP20230809TT patent/HRP20230809T1/hr unknown
- 2016-09-09 RS RS20230603A patent/RS64481B1/sr unknown
- 2016-09-09 EP EP23176559.5A patent/EP4275750B1/en active Active
- 2016-09-09 MX MX2018003023A patent/MX392677B/es unknown
- 2016-09-09 FI FIEP16845181.3T patent/FI3347002T3/fi active
- 2016-09-09 KR KR1020227009418A patent/KR102547164B1/ko active Active
- 2016-09-09 CN CN201680052760.4A patent/CN108289870A/zh active Pending
- 2016-09-09 PT PT168451813T patent/PT3347002T/pt unknown
- 2016-09-09 CN CN202310582365.9A patent/CN116712422A/zh active Pending
- 2016-09-09 CA CA2997376A patent/CA2997376C/en active Active
- 2016-09-09 SM SM20260257T patent/SMT202600257T1/it unknown
-
2018
- 2018-03-09 MX MX2022003128A patent/MX2022003128A/es unknown
-
2020
- 2020-09-28 JP JP2020161995A patent/JP7128536B2/ja active Active
-
2021
- 2021-09-17 US US17/477,886 patent/US20220096406A1/en not_active Abandoned
-
2022
- 2022-08-12 JP JP2022128786A patent/JP2022145949A/ja active Pending
-
2023
- 2023-09-06 US US18/462,238 patent/US20230414541A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023627A patent/JP2025065545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020200352A5 (enExample) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| FI3347002T3 (fi) | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa | |
| RU2009120048A (ru) | Способы и комбинированные средства для лечения болезни альцгеймера | |
| Narver | Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice | |
| Sighencea et al. | From fundamentals to innovation in Alzheimer’s disease: molecular findings and revolutionary therapies | |
| JP7049683B2 (ja) | トラピジルを使用する錐体外路症候群の処置 | |
| Cao et al. | Effect of bispectral index-guided anesthesia on consumption of anesthetics and early postoperative cognitive dysfunction after liver transplantation: an observational study | |
| JP2023181398A (ja) | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 | |
| Walczak et al. | Chemobrain as a product of growing success in chemotherapy-focus on glia as both a victim and a cure | |
| Ala et al. | A critical review of therapeutic interventions in sickle cell disease: Progress and challenges | |
| JP2023531930A5 (enExample) | ||
| Reneerkens et al. | The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans | |
| Szczeklik et al. | Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis | |
| Bajaj et al. | Cessation in root development: Ramifications of′ Stevens-Johnson′ syndrome | |
| JPH10167960A (ja) | 肝細胞ガン再発抑制剤 | |
| Lim et al. | A case of Stevens-Johnson syndrome probably induced by herbal medicine | |
| Ilia | Stop Aging Disease! ICAD 2014 | |
| TWI472519B (zh) | 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能 | |
| JP2017197554A (ja) | アルツハイマー病を治療する方法及び医薬品 | |
| JP2018505899A (ja) | ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン | |
| TWI899092B (zh) | 用於神經退化性病症之治療之銅複合物 | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| Long et al. | Combined edaravone and D1-3-n-butylphthalide antioxidant therapy for paraquat poisoning | |
| JP6738797B2 (ja) | レット症候群治療薬 |